An update for healthcare professionals and patients on Increlex® (mecasermin) Injection
This important medicine, and all associated activities, will be transferred to Eton Pharmaceuticals following the signing of an asset transfer agreement. This agreement is expected to complete at the end of 2024.
For both companies, our main priority is ensuring you have continuous supply of Increlex throughout the transition. For more information, please contact www.ipsenmedicalinformation.com.
Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio
Ipsen to present data across five rare liver diseases at AASLD 2025
Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
Ipsen announces sale of Priority Review Voucher for $158m
Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation
Ipsen and Medetia join forces to accelerate early research in rare disease
Offering support to those impacted in Turkey & Syria